We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares
ORTX

Delisted

ORTX was delisted on the 23rd of January, 2024.

Back to rankings

81 hedge funds and large institutions have $392M invested in Orchard Therapeutics plc American Depositary Shares in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 18

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

9% more funds holding

Funds holding: 74 → 81 (+7)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

19% less capital invested

Capital invested by funds: $485M → $392M (-$92.6M)

Holders
81
Holders Change
+7
Holders Change %
+9.46%
% of All Funds
1.66%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
18
Increased
30
Reduced
18
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$12.1M
2
ROTUOC
Regents of the University of California
California
+$7.8M
3
CC
Casdin Capital
New York
+$6.18M
4
Morgan Stanley
Morgan Stanley
New York
+$5.58M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.1M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$14.7M
2
ACH
ArrowMark Colorado Holdings
Colorado
-$9.6M
3
DCM
Driehaus Capital Management
Illinois
-$9.19M
4
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$5.48M
5
VC
Vivo Capital
California
-$2.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
51
Geode Capital Management
Massachusetts
$184K +$98.9K +1,079 +54%
EGM
52
Engineers Gate Manager
New York
$183K +$160K +1,750 +135%
Squarepoint
53
Squarepoint
New York
$154K +$68.1K +743 +41%
Legal & General Group
54
Legal & General Group
United Kingdom
$154K +$128K +1,397 +120%
Mitsubishi UFJ Asset Management
55
Mitsubishi UFJ Asset Management
Japan
$130K +$42.9K +468 +28%
VF
56
Virtu Financial
New York
$124K +$189K +2,065 New
GCP
57
GSA Capital Partners
United Kingdom
$124K +$190K +2,071 New
FA
58
Forefront Analytics
Pennsylvania
$115K +$175K +1,913 New
Arrowstreet Capital
59
Arrowstreet Capital
Massachusetts
$111K +$169K +1,850 New
WCM
60
Weld Capital Management
New York
$109K +$40K +437 +32%
CAN
61
Cetera Advisor Networks
California
$88K +$135K +1,470 New
MWNA
62
Marshall Wace North America
New York
$87K +$132K +1,446 New
LI
63
Leap Investments
Illinois
$73K +$111K +1,210 New
IAA
64
Ironsides Asset Advisors
North Carolina
$70K – – –
Two Sigma Advisers
65
Two Sigma Advisers
New York
$69K -$105K -1,150 -50%
Zurich Cantonal Bank
66
Zurich Cantonal Bank
Switzerland
$68K – – –
Citigroup
67
Citigroup
New York
$32K -$70K -764 -59%
PFO
68
Pathstone Family Office
New Jersey
$26K – – –
UBS Group
69
UBS Group
Switzerland
$23K +$92 +1 +0.3%
AA
70
AlphaCentric Advisors
Puerto Rico
$22K +$33K +360 New
TRCT
71
Tower Research Capital (TRC)
New York
$14K +$21K +229 New
APA
72
American Portfolios Advisors
New York
$12.2K +$8.24K +90 +80%
LC
73
Lindbrook Capital
California
$6K +$9.16K +100 New
SFS
74
Sowell Financial Services
Arkansas
$4K -$32.2K -352 -84%
Wells Fargo
75
Wells Fargo
California
$4K – – –
1 2
3
4

ORTX Hedge Fund Activity: Q2 2020 in Review

81 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q2 2020, worth a combined $392M — down 19% from $485M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ORTX positions and 11 closed out — a net gain of 7 holders — while 30 added to existing stakes and 18 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $12.1M. The largest seller was Deerfield Management, cutting an estimated $14.7M.

  • 81 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q2 2020, up from 74 in Q1 2020.
  • Funds reported $392M of Orchard Therapeutics plc American Depositary Shares stock for Q2 2020, down 19% quarter-over-quarter.
  • 18 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q2 2020 and 11 closed out, a net change of +7 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q2 2020 was JP Morgan Chase, an estimated $12.1M added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q2 2020 was Deerfield Management, an estimated $14.7M sold.

Based on aggregated 13F filings for Q2 2020.